Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies
SA Tuazon, A Li, T Gooley, TW Eunson… - …, 2019 - Wiley Online Library
BACKGROUND The clinical and procedural parameters that affect the optimal collection of
lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined …
lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined …
Autologous lymphapheresis for the production of chimeric antigen receptor T cells
BACKGROUND The first step in manufacturing chimeric antigen receptor (CAR) T cells is to
collect autologous CD3+ lymphocytes by apheresis. Patients, however, often have …
collect autologous CD3+ lymphocytes by apheresis. Patients, however, often have …
Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL
F Korell, S Laier, S Sauer, K Veelken, H Hennemann… - Cells, 2020 - mdpi.com
Background: T lymphocyte collection through leukapheresis is an essential step for chimeric
antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily …
antigen receptor T (CAR-T) cell therapy. Timing of apheresis is challenging in heavily …
Get off on the right foot: how to plan an efficient leukocytapheresis to collect T cells for CAR T-cell manufacturing
JA Piñeyroa, J Cid, M Lozano - Transfusion Medicine and Hemotherapy, 2023 - karger.com
Background: The major drug regulatory agencies have approved chimeric antigen receptor
(CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is …
(CAR) T cells for the treatment of some B-cell lymphoproliferative diseases. Their use is …
Optimization of lymphapheresis for manufacturing autologous CAR-T cells
I Yamanaka, T Yamauchi, T Henzan, T Sakoda… - International journal of …, 2021 - Springer
Collection of CD3+ lymphocytes via lymphapheresis is essential for manufacturing
autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures …
autologous chimeric antigen receptor (CAR) T cells. Optimization of timing and procedures …
Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients
D Hutt, B Bielorai, B Baturov, I Z'orbinski, N Ilin… - … and Apheresis Science, 2020 - Elsevier
Background Autologous CD19 chimeric-antigen receptor (CAR) T-cells are an effective
salvage therapy for patients with relapsed or refractory B cell malignancies. The essential …
salvage therapy for patients with relapsed or refractory B cell malignancies. The essential …
Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
DF Stroncek, DW Lee, J Ren, M Sabatino… - Journal of translational …, 2017 - Springer
Abstract Background Clinical trials of Chimeric Antigen Receptor (CAR) T cells
manufactured from autologous peripheral blood mononuclear cell (PBMC) concentrates for …
manufactured from autologous peripheral blood mononuclear cell (PBMC) concentrates for …
Timely leukapheresis may interfere with the “fitness” of lymphocytes collected for CAR-T treatment in high risk DLBCL patients
Simple Summary Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the
treatment of specific hematological diseases, but is unsuccessful in around 60% of patients …
treatment of specific hematological diseases, but is unsuccessful in around 60% of patients …
Important aspects of T‐cell collection by apheresis for manufacturing chimeric antigen receptor T cells
M Paroder, N Le, HP Pham… - Advances in Cell and …, 2020 - Wiley Online Library
Chimeric antigen receptor (CAR)‐T cells have proven to be an effective cancer therapy for
CD19‐expressing neoplasms. Efforts to optimize the manufacturing process can help to …
CD19‐expressing neoplasms. Efforts to optimize the manufacturing process can help to …
[HTML][HTML] A clinically applicable prediction model to improve T cell collection in chimeric antigen receptor T cell therapy
T Jo, S Yoshihara, A Hada, Y Arai, T Kitawaki… - … and Cellular Therapy, 2022 - Elsevier
As chimeric antigen receptor (CAR) T cell therapy targeting CD19 has shown favorable
outcomes in patients with relapsed or refractory (r/r) mature B cell lymphomas and B cell …
outcomes in patients with relapsed or refractory (r/r) mature B cell lymphomas and B cell …